Skip to main content
Fig. 1 | Journal of Experimental & Clinical Cancer Research

Fig. 1

From: PEGylated recombinant human hyaluronidase (PEGPH20) pre-treatment improves intra-tumour distribution and efficacy of paclitaxel in preclinical models

Fig. 1

Antitumor activity of PEGPH20 and PTX in SKOV3 (A) and SKOV3/HAS3 (B) models. Tumour bearing mice (n = 9 and n = 8 in SKOV3 and SKOV3/HAS3 experiments, respectively) were randomized to receive PTX 20 mg/kg q7dx3 with or without the pre-treatment with PEGPH20 0.1 mg/kg, or PEGPH20 alone. In the SKOV3/HAS3 but not in the parental SKOV3 model, hyaluronidase combined with PTX dramatically enhanced the antitumor activity (** Wilcoxon Rank-Sum test stratified by intervals: p-value< 0.001 comparing the entire experimental groups)

Back to article page